Table 1.
Baseline Characteristics of Rheumatoid Arthritis Cohorts by Treatment Group
| Cross-sectional RA cohort | Methotrexate initiators | Anti-TNFa initiators | Abatacept initiators | |
|---|---|---|---|---|
| Number of subjects | 77 | 11 | 33 | 27 |
| Age, mean (SD) | 46.8 (14.2) | 45.3 (12.4) | 54.1 (11.5) | 49.5 (13.4) |
| Gender female % | 83.1 | 63.6 | 90.9 | 85.2 |
| Caucasian (%) | 70.1 | 63.6 | 81.8 | 77.8 |
| Disease duration (median years, IQR) | 7 (6) | 3 (3) | 11.5 (16.5) | 12 (18) |
| Baseline tender joint count (median, IQR) | 12 (12.2) | 11 (15) | 13 (15) | 11 (14) |
| Baseline swollen joint count (median, IQR) | 6 (7) | 5 (6) | 6 (9) | 7 (8.5) |
| Baseline DAS28 (mean, SD) | 5.7 (1.5) | 6.2 (1.3) | 5.7 (1.5) | 5.6 (1.3) |
| Achieved DAS28 (mean, SD) | N/A | 4.3 (1.3) | 4.9 (1.5) | 5.2 (1.2) |
| Background MTX % | N/A | N/A | 50 | 65.4 |
N/A not available
a
Note: anti-TNF therapies included adalimumab, etanercept and infliximab